GlassScriptPhysician profile
David Z Yao
NPI 1740440973
$25,032.11
in general payments reported to CMS, 2019-2025
41 companies · $3,453 in 2025
The $3,453 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,710 · 2020: $2,929 · 2021: $4,892 · 2022: $4,262 · 2023: $2,816 · 2024: $3,970 · 2025: $3,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,813 · Travel and Lodging: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,812.72 |
| Travel and Lodging | $425.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $14,412.64 | 2019-2025 | Cardiomems, Jot Dx, Triclip |
| Biotronik INC. | $1,452.71 | 2019-2021 | |
| Amgen INC. | $1,075.86 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $870.72 | 2019-2025 | Watchman Flx, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| E.R. Squibb & Sons, L.L.C. | $825.43 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $737.11 | 2021-2025 | |
| Medtronic, INC. | $700.99 | 2022-2025 | Corevalve Evolut R, Hawkone, Linq II |
| Pfizer INC. | $665.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $586.99 | 2020-2025 | Farxiga, Airsupra, Lokelma |
| Edwards Lifesciences Corporation | $328.43 | 2021-2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $314.14 | 2021-2022 | |
| Novo Nordisk INC | $311.18 | 2022-2025 | Wegovy, Ozempic |
| Regeneron Healthcare Solutions, INC. | $304.13 | 2024-2025 | Evkeeza, Praluent |
| Esperion Therapeutics, INC. | $276.17 | 2021-2025 | Nexletol |
| Paragonix Technologies, INC. | $260.83 | 2024 | Baroguard, Lungguard, Sherpapak |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.